Trial Profile
Assessment and Follow-up of Patients With Non-small Cell Lung Cancer (NSCLC) Treated With Nivolumab Under the French Temporary Authorization for Use (ATU) Program
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 08 Jan 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Acronyms CLINIVO
- 06 Jan 2021 Status changed from active, no longer recruiting to completed.
- 11 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 13 May 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.